A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies.
Ontology highlight
ABSTRACT: Impairing the division of cancer cells with genotoxic small molecules has been a primary goal to develop chemotherapeutic agents. However, DNA mismatch repair (MMR)-deficient cancer cells are resistant to most conventional chemotherapeutic agents. Here we have identified baicalein as a small molecule that selectively kills MutSα-deficient cancer cells. Baicalein binds preferentially to mismatched DNA and induces a DNA damage response in a MMR-dependent manner. In MutSα-proficient cells, baicalein binds to MutSα to dissociate CHK2 from MutSα leading to S-phase arrest and cell survival. In contrast, continued replication in the presence of baicalein in MutSα-deficient cells results in a high number of DNA double-strand breaks and ultimately leads to apoptosis. Consistently, baicalein specifi
SUBMITTER: Zhang Y
PROVIDER: S-EPMC5033673 | biostudies-literature | 2016 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA